ARVN Arvinas, Inc.

$8.45▼ -2.99% Healthcare Other
After hours $8.45▲ +0.00% Sep 11, 7:30 PM ET
Volume 908.5K Avg Volume (10D) 586.1K
Key Metrics & Fundamentals
Market Cap
$545.20M
P/E Ratio
32.5
Div Yield
–%
52W Range
6.97 - 14.51
% vs 50 MA
-3.07%
% vs 200 MA
-19.37%
RSI-14
39.7
MACD Histogram
-0.1300
Beta (1Y vs SPY)
1.18
Free Cash Flow
-$48.50M
Gross Rev
$249.70M
Gross Profit
$249.70M
EBITDA
$165.30M
COGS
–
Operating Exp
$85.60M
Operating Income
$164.10M
EBIT
$164.10M
Pretax Income
$169.60M
Net Income
$169.40M
EPS (Diluted)
2.58
Price & Volume History
Loading chart…
Recent News
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
Insider Monkey · Sep 9, 2026 6:22 AM
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 8:01 PM
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Zacks · Sep 3, 2026 3:50 PM
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 1, 2026 8:01 PM
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 11, 2026 6:05 PM
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
MT Newswires · Aug 10, 2026 4:01 PM
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating
MT Newswires · Aug 10, 2026 9:40 AM
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Zacks · Aug 6, 2026 4:00 PM
Arvinas, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 4, 2026 9:41 PM
Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating
MT Newswires · Aug 4, 2026 3:41 PM
Financial Overview - Income Statement Quarterly

See ARVN's money flow as a full page

Social Sentiment
Avg +0.80 · 2 posts
DiscussionTurn around story
r/stocks · Jul 25, 2026
The author expresses high conviction and desire to protect principal while holding Arvanx.
positive +0.60
DDNewsDiscussionPriceTarget$ARVN DD - First-in-class PROTAC cancer drug just got FDA approval
r/wallstreetbets · May 1, 2026
The post highlights FDA approval, validation of the PROTAC platform, and a shift in ARVN's status. Strong bullish sentiment.
very_positive +1.00
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙